Novocure Ltd. (NVCR) News
Filter NVCR News Items
NVCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCR News Highlights
- NVCR's 30 day story count now stands at 11.
- Over the past 10 days, the trend for NVCR's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- CELL, LUNG and ROOT are the most mentioned tickers in articles about NVCR.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
Stocks Mixed As VIX Extends LowsStocks are struggling for direction midday. |
Novocure Crashes 43% As Critics Question Its 'Profound' Impact In Lung Cancer TreatmentA medical device from Novocure extended overall survival for lung cancer patients, but the company's shares crashed on muddy test results. |
Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops +40%On Tuesday, Novocure received a positive adjustment to its Relative Strength (RS) Rating, from 63 to 79 based on previous day trading. Then news broke and the bottom fell out. When looking for the best stocks to buy and watch, Always keep a close on eye on relative price strength. |
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining DoubtsZai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) presented results from the phase 3 LUNAR trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology Annual Meeting. The LUNAR trial met its primary endpoint with a statistically significant and clinically meaningful 3-month improvement in median overall survival (OS) when TTFields therapy was added t |
These 2 Nasdaq Stocks Are Plunging. Here's WhySmall-cap stocks soared on Tuesday at midday, which helped drive the Nasdaq Composite (NASDAQINDEX: ^IXIC) to gains of nearly half a percent. Within the Nasdaq, though, there were several stocks that lost ground. NovoCure (NASDAQ: NVCR) suffered a steep drop in its share price following its latest news on a key treatment option for cancer patients. |
Why NovoCure Stock Is Crashing TodayWhat happened Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company announced data for its Tumor Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC) that it's presenting today at the American Society of Clinical Oncology (ASCO) annual meeting. |
UPDATE 2-Novocure's lung cancer device extends survival in late-stage studyNovocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically significant improvement in extending overall survival among patients in a late-stage study. The device, used with certain chemotherapies and immunotherapies, helps in creating electric fields that disrupt cancer cell growth. Data from the study showed the device, along with a class of immunotherapies know as immune checkpoint inhibitors (ICI), extended survival by 8 months compared to patients treated with ICI alone. |
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based TherapiesTumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in |
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based TherapiesROOT, Switzerland, June 06, 2023--Novocure today is presenting positive results from the phase 3 LUNAR clinical trial in non-small cell lung cancer at the 2023 ASCO Annual Meeting. |
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and EducationROOT, Switzerland, June 01, 2023--Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education. |